A potential signature of eight long non-coding RNAs predicts survival in patients with non-small cell lung cancer

Abstract

BackgroundAccumulated evidence suggests that dysregulated expression of long non-coding RNAs (lncRNAs) may play a critical role in tumorigenesis and prognosis of cancer, indicating the potential utility of lncRNAs as cancer prognostic or diagnostic markers. However, the power of lncRNA signatures in predicting the survival of patients with non-small cell lung cancer (NSCLC) has not yet been investigated.MethodsWe performed an array-based transcriptional analysis of lncRNAs in large patient cohorts with NSCLC by repurposing microarray probes from the gene expression omnibus database. A risk score model was constructed based on the expression data of these eight lncRNAs in the training dataset of NSCLC patients and was subsequently validated in other two independent NSCLC datasets. The biological implications of prognostic lncRNAs were also analyzed using the functional enrichment analysis.ResultsAn expression pattern of eight lncRNAs was found to be significantly associated with overall survival (OS) of NSCLC patients in the training dataset. With the eight-lncRNA signature, patients of the training dataset could be classified into high- and low-risk groups with significantly different OS (median survival 1.67 vs. 6.06 years, log-rank test p = 4.33E−09). The prognostic power of eight-lncRNA signature was further validated in other two non-overlapping independent NSCLC cohorts, demonstrating good reproducibility and robustness of this eight-lncRNA signature in predicting OS of NSCLC patients. Multivariate regression and stratified analysis suggested that the prognostic power of the eight-lncRNA signature was independent of clinical and pathological factors. Functional enrichment analyses revealed potential functional roles of the eight prognostic lncRNAs in tumorigenesis.ConclusionsThese findings indicate that the eight-lncRNA signature may be an effective independent prognostic molecular biomarker in the prediction of NSCLC patient survival.Electronic supplementary materialThe online version of this article (doi:10.1186/s12967-015-0556-3) contains supplementary material, which is available to authorized users.

Long non-coding RNA NEAT1 regulates E2F3 expression by competitively binding to miR-377 in non-small cell lung cancer

“…Moreover, lncRNAs also have the potential function as diagnostic or prognostic markers of cancer (4)(5)(6)(7)(8)(9)(10). Nuclear enriched abundant transcript 1 (NEAT1) is a nuclear-restricted lncRNA that has two isoforms: NEAT1-1 and NEAT1-2 (11).…”

Long Non-Coding RNAs and Their Roles in Non-Small-Cell Lung Cancer

“…For instance, expression levels of lncRNAs RP11-21L23.2 , GPR158-AS1 , RP11-701P16.5 , and RP11-379F4.4 were negatively correlated with NSCLC patients’ overall survival. Conversely, expression levels of lncRNAs CTD-2358C21.4 , RP11-94L15.2 , KCNK15-AS1 , and AC104134.2 were positively associated with the overall survival of NSCLC patients [93].…”

Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma

“…Those probes that were uniquely mapped to the human genome and lncRNA genes with no mismatch were retained for further analysis. Finally, 3215 (covering 2330 lncRNAs for HG-U133 Plus_2.0) and 855 (covering 663 lncRNAs for HG-U133A) lncRNA-specific probes were obtained by cross-referencing the chromosomal position of probes and the chromosomal position of lncRNA genes according to previous studies [30–32]. For those lncRNAs with multiple probes, the expression values of lncRNAs were produced by using the mean value of multiple probes.…”